MYOGEN REPORTS RESULTS OF PAH STUDY

A A

Myogen has reported that a late-stage trial of its ambrisentan found the drug delayed worsening and improved symptoms in patients with pulmonary arterial hypertension (PAH).

The Phase III study found that ambrisentan also increased PAH patients' capacity for exercise, and was well-tolerated. The most frequent adverse events were headaches, which were experienced by 12.7 percent of patients in the 5 mg dose group and by 7.8 percent of patients in the 2.5 mg dose group, compared to 6.2 percent in the placebo group.